STT 06
Alternative Names: Anti-CD223 antibody - STCube Pharmaceuticals; Anti-LAG-3 antibody - STCube Pharmaceuticals; Anti-lymphocyte activation gene 3 antibody - STCube Pharmaceuticals; STT-06Latest Information Update: 28 Aug 2022
At a glance
- Originator STCube Pharmaceuticals
- Class Antibodies; Antineoplastics
- Mechanism of Action CD223 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)
- 31 Jul 2018 STT 06 is available for licensing as of 31 Jul 2018.
- 31 Jul 2018 Early research in Cancer in South Korea (Parenteral) (STCube Pharmaceuticals pipeline, July 2018)